logo

CURIS INC(NSDQ:CRIS)
Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis'' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.
# Employees: 34
Address: 45 Moulton Street,Cambridge,MA,USA
Phone: 617 503-6500
Fax: 617 503-6501
Website: www.curis.com
Email: info@curis.com
Sector: Medical
Industry: MED-BIOMED/GENE
Executive Officers
James R. McNab Jr. (Chmn.)
Daniel R. Passeri (Presi.; C.E.O.; Dir.)
Mark W. Noel Ph.D. (V.P. Tech. Mngmt. & Busi. Devlop.)
Changgeng Qian Ph.D (V.P.; Discovery and Preclinical Research)
Michael P. Gray (C.O.O.; C.F.O.,)
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
Last Earnings Date: 9/30/2009
Next Earnings Date(Expected): 2/9/2010
Mean EPS (Next Qtr): ($0.05)
Mean EPS (Year): ($0.16)
Mean Estimate(Long Term): ($0.01)
P/E Ratio(Based on EPS estimate): -0.010
Number of Estimates: 4
Shares Performance
Period CRIS Compare to S&P
YTD 201.33 % 149.39 %
4 Weeks 5.12 % 3.98 %
12 Weeks 13.57 % 7.07 %
Shares Information
Analyst Coverage: Y
Avg Volume: 218664
Shares Outstanding: 66M
Market Cap: $0.15B
52 Week High: $2.53
52 Week Low: $0.68
P/E Ratio: -0.010
PEG Ratio: -0.010
Split: On 1/1/1990 CRIS split by factor of 0.100
Earnings Performance
EPS Growth in Last Quarter: 14.29 %
EPS Growth in Last Year: 14.29 %
Sales Growth in Last Quarter: 1,114.29 %
Sales Growth in Last Quarter: 779.31 %
Financials
Qtr Book Value: $3.70
Cash Flow/Share: ($0.01)
Change in Payout Ratio: -0.010
Price/Sales: 15.060
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia